NLTX
Income statement / Annual
Last year (2022), Neoleukin Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, Neoleukin Therapeutics, Inc.'s net income was -$56.02 M.
See Neoleukin Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$6,000.00
|
$451,000.00
|
$0.00
|
$25.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$6,000.00 |
$451,000.00 |
$0.00 |
$25.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
1 |
1 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$41.13 M
|
$39.16 M
|
$24.34 M
|
$4.42 M
|
$41.79 M
|
$36.27 M
|
$28.38 M
|
$15.80 M
|
$18.08 M
|
$7.54 M
|
| General & Administrative
Expenses |
$17.97 M
|
$21.54 M
|
$17.21 M
|
$18.83 M
|
$15.84 M
|
$14.85 M
|
$9.26 M
|
$5.54 M
|
$4.30 M
|
$1.78 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$17.97 M
|
$21.54 M
|
$17.21 M
|
$18.83 M
|
$15.84 M
|
$14.85 M
|
$9.26 M
|
$5.54 M
|
$4.30 M
|
$1.78 M
|
| Other Expenses |
-$42,000.00 |
$6,000.00 |
-$44,000.00 |
-$8,000.00 |
-$445,000.00 |
-$39,000.00 |
-$43,000.00 |
-$369,000.00 |
-$254,890.00 |
$0.00 |
| Operating Expenses |
$59.10 M |
$60.70 M |
$41.55 M |
$23.24 M |
$57.62 M |
$51.12 M |
$37.65 M |
$21.34 M |
$22.38 M |
$9.38 M |
| Cost And Expenses |
$59.10 M |
$60.70 M |
$41.55 M |
$23.24 M |
$57.62 M |
$51.12 M |
$37.65 M |
$21.34 M |
$22.38 M |
$9.38 M |
| Interest Income |
$1.58 M |
$19,000.00 |
$490,000.00 |
$1.54 M |
$1.56 M |
$998,000.00 |
$619,000.00 |
$0.00 |
$0.00 |
$26,321.00 |
| Interest Expense |
$1.58 M |
$0.00 |
$0.00 |
$1,000.00 |
$4,000.00 |
$4,000.00 |
$1,000.00 |
$99,000.00 |
$461,587.00 |
$42,923.00 |
| Depreciation &
Amortization |
$2.61 M
|
$2.28 M
|
-$13.84 M
|
$49.59 M
|
$1.04 M
|
$940,000.00
|
$644,000.00
|
-$421,000.00
|
$135,946.00
|
$59,571.00
|
| EBITDA |
-$56.49 M
|
-$60.70 M
|
-$47.56 M
|
-$21.37 M
|
-$31.51 M
|
-$50.16 M
|
-$37.07 M
|
-$21.71 M
|
-$24.38 M
|
-$9.68 M
|
| EBITDA Ratio |
0 |
-10116.33 |
-105.46 |
0 |
-1.26 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
-10116.33
|
-74.78
|
0
|
-1.3
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.54 M
|
$6,000.00
|
$7.83 M
|
$1.52 M
|
$1.04 M
|
$936,000.00
|
$643,000.00
|
-$520,000.00
|
$487,598.00
|
$641,240.00
|
| Income Before Tax |
-$57.56 M |
-$60.69 M |
-$33.28 M |
-$69.44 M |
-$31.59 M |
-$50.18 M |
-$37.00 M |
-$21.86 M |
-$24.03 M |
-$8.73 M |
| Income Before Tax Ratio
|
0
|
-10115.33
|
-73.78
|
0
|
-1.26
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.54 M |
-$2.28 M |
-$8.32 M |
-$7,000.00 |
-$1.04 M |
-$940,000.00 |
-$644,000.00 |
$421,000.00 |
-$222.00 |
-$5,044.00 |
| Net Income |
-$56.02 M |
-$58.42 M |
-$24.96 M |
-$69.44 M |
-$31.59 M |
-$50.18 M |
-$37.00 M |
-$21.86 M |
-$23.82 M |
-$9.30 M |
| Net Income Ratio |
0 |
-9735.83 |
-55.33 |
0 |
-1.26 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.01 |
-1.06 |
-0.48 |
-2.57 |
-1.34 |
-2.14 |
-1.96 |
-1.73 |
-2.75 |
-0.93 |
| EPS Diluted |
-1.01 |
-1.06 |
-0.48 |
-2.57 |
-1.34 |
-2.14 |
-1.96 |
-1.73 |
-2.75 |
-0.93 |
| Weighted Average Shares
Out |
$11.04 M
|
$11.01 M
|
$10.37 M
|
$5.41 M
|
$4.70 M
|
$4.69 M
|
$3.78 M
|
$2.53 M
|
$1.73 M
|
$1.17 M
|
| Weighted Average Shares
Out Diluted |
$11.04 M
|
$11.01 M
|
$10.37 M
|
$5.41 M
|
$4.70 M
|
$4.69 M
|
$3.78 M
|
$2.53 M
|
$1.73 M
|
$1.17 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
